WASHINGTON & NORWICH, Conn. — AVS Bio, a portfolio company of Arlington Capital Partners, has acquired ImmunoPrecise Antibodies (Europe) B.V. from ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), expanding its European presence and adding advanced capabilities in antibody discovery, protein expression, and organoid growth factor manufacturing.
With facilities in Utrecht and Oss, Netherlands, IPA Europe offers antibody discovery, engineering, and characterization services, along with recombinant protein production for research and pre-clinical use. The company will continue operating under its existing management as a strategic European hub for AVS Bio, serving pharmaceutical and biotech clients globally in both human and animal health markets.
“IPA Europe brings exceptional technical capabilities and a reputation for scientific rigor that aligns perfectly with our mission,” said Jac Price, CEO of AVS Bio. “This acquisition significantly enhances our service offering and geographic reach.”
Arlington Capital Partners partner Malcolm Little said the deal reflects AVS Bio’s strategy of expanding through organic growth and targeted acquisitions, particularly in upstream biologics research and development.
IPA Europe general managers Ilse Roodink and Roland Romijn said joining AVS Bio will allow them to scale operations, invest in next-generation technologies, and offer end-to-end biologics development services.
The acquisition follows Arlington’s track record of building companies in regulated industries critical to healthcare and national security. Edgemont Partners acted as exclusive sell-side advisor to ImmunoPrecise Antibodies Ltd. in the transaction.
